Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Other Non-Current Assets (2016 - 2026)

Cartesian Therapeutics (RNAC) has disclosed Other Non-Current Assets for 11 consecutive years, with $1.7 million as the latest value for Q1 2026.

  • For Q1 2026, Other Non-Current Assets rose 1.86% year-over-year to $1.7 million; the TTM value through Mar 2026 reached $1.7 million, up 1.86%, while the annual FY2025 figure was $5.6 million, 971.62% up from the prior year.
  • Other Non-Current Assets hit $1.7 million in Q1 2026 for Cartesian Therapeutics, down from $5.6 million in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $5.6 million in Q4 2025 and bottomed at $518000.0 in Q4 2024.
  • Average Other Non-Current Assets over 5 years is $1.7 million, with a median of $1.6 million recorded in 2022.
  • Year-over-year, Other Non-Current Assets decreased 13.94% in 2023 and then soared 971.62% in 2025.
  • Cartesian Therapeutics' Other Non-Current Assets stood at $1.6 million in 2022, then dropped by 13.94% to $1.4 million in 2023, then tumbled by 62.38% to $518000.0 in 2024, then skyrocketed by 971.62% to $5.6 million in 2025, then tumbled by 69.37% to $1.7 million in 2026.
  • According to Business Quant data, Other Non-Current Assets over the past three periods came in at $1.7 million, $5.6 million, and $1.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.